Wedbush restated their outperform rating on shares of Unity Biotechnology (NASDAQ:UBX – Get Rating) in a report published on Thursday morning, Benzinga reports. Wedbush currently has a $35.00 price objective on the stock.
Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a buy rating and issued a $10.00 price target on shares of Unity Biotechnology in a report on Wednesday, February 15th. Mizuho lowered their price target on Unity Biotechnology from $80.00 to $12.00 and set a buy rating for the company in a report on Wednesday, November 16th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of Buy and an average target price of $34.25.
Unity Biotechnology Stock Performance
Shares of NASDAQ UBX opened at $3.78 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.92 and a quick ratio of 6.12. The business has a 50-day simple moving average of $4.31 and a two-hundred day simple moving average of $3.86. Unity Biotechnology has a fifty-two week low of $2.09 and a fifty-two week high of $18.50.
Institutional Inflows and Outflows
About Unity Biotechnology
Unity Biotechnology, Inc operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.
- Get a free copy of the StockNews.com research report on Unity Biotechnology (UBX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.